- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03033836
Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women (TRANSViiV)
Pilot Study of Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women
Prospective, open, single-arm trial of dolutegravir-tenofovir and emtricitabine or lamivudine (DTG-TDF-FTC or 3TC) in antiretroviral (ART) naïve HIV transgender women (TGW).
The primary objective of this pilot study is to determine the retention in care of TGW treated with DTG-TDF-FTC or 3TC
Secondary objectives:
- To evaluate the efficacy of the antiretroviral regimen at week 48 ;
- To describe the safety and tolerability of this regimen;
- To evaluate adherence across 48 weeks;
- To determine the patient satisfaction with this regimen;
- To identify individual, social and contextual factors associated with adherence and retention.
Study Overview
Detailed Description
The primary objective of this pilot study is to determine the retention in care of TGW treated with DTG-TDF-FTC.
The primary objective will be assessed by the proportion of individuals that provide information on ART use and virological outcomes at the end of the study:
- Retention under care: Proportion of enrolled and dosed individuals that provide clinical information up to 48 weeks of follow up.
- Retention on treatment: Proportion of enrolled and dosed individuals that receive study drugs up to 48 weeks of follow up.
Secondary objectives:
- To evaluate the efficacy of the antiretroviral regimen at week 48 ;
- To describe the safety and tolerability of this regimen;
- To evaluate adherence across 48 weeks;
- To determine the patient satisfaction with this regimen;
- To identify individual, social and contextual factors associated with adherence and retention.
The secondary objectives will be evaluated using the following endpoints:
- Proportion of patients with HIV-1 RNA levels of less than 50 copies/mL at 48 weeks of treatment by the IIT-exposed snapshot FDA algorithm;
- Frequency, type and severity of adverse events and laboratory abnormalities;
- Pill count, analogue visual scale for adherence in each visit;
- Changes in the scores of stigma and discrimination scales , quality of life, social support and anxiety and depression (BERGER, WBI,DUKE,CES-D,STAI) at bsl, 4,24, and 48 weeks e;.Changes in the score scales of sexual behaviors, use of drug /alcohol at bsl and at each visit .
f. Through association of baseline individual, social and contextual characteristics with percentage of adherence and retention at 48 weeks.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Buenos Aires
-
Ciudad de Buenos Aires, Buenos Aires, Argentina, C1202ABB
- Fundación Huésped
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- HIV-1 positive serology by at least two different serological tests (rapid test, ELISA, Western Blot) or a viral load higher than 3,000 copies/mL.
- 18 years and older.
- Self-identified as TGW
- ART naïve.
- Written informed consent provided.
Exclusion Criteria:
- Genotypic resistance to TDF and/or FTC as per IAS-USA resistance panel 2013.
- Alcohol or drug use that might affect adherence.
- Concomitant use of lipid-lowering drugs, interferon, interleukin-2, cytotoxic chemotherapy, dofetilide (or pilsicainide) or immunosuppressors, antacids drugs containing Ca++ and or Mg++ at study entry.
- Opportunistic infection (CDC "C" category) or other disease and/or clinical conditions that, in the investigator's opinion, would compromise the patient's safety or outcome of the study; including malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia.
- Treatment with any of the following agents within 28 days of screening: radiation therapy; cytotoxic chemotherapeutic agents; any immunomodulators that alter immune responses or treatment with an HIV-1 immunotherapeutic vaccine within 90 days of screening or exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of the investigational product.
- Contraindication to any of the study drugs (history of renal diseases, lab abnormalities grade 4 or any other clinical condition prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements).
- Anticipated need for Hepatitis C virus (HCV) therapy during the study.
- Creatinine clearance of <50 mL/min via Cockroft-Gault method.
- Subjects with moderate to severe hepatic impairment (Class B or greater) as determined by Child-Pugh classification.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: single arm
ARV treatment based on Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine
|
Dolutegravir 50 mg QD plus co-formulated emtricitabine 200 mg/tenofovir 300 mg QD.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of transgender women retained in care at week 48
Time Frame: 48 weeks
|
Proportion of enrolled and dosed individuals that complete protocol defined visits during 48 weeks of follow up. Retention under care: Proportion of enrolled and dosed individuals that provide clinical information up to 48 weeks of follow up. Retention on treatment: Proportion of enrolled and dosed individuals that receive study drugs up to 48 weeks of follow up. |
48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of individuals with HIV RNA undetectable at week 48
Time Frame: 48 weeks
|
Proportion of patients with HIV-1 RNA levels less than 50 copies/mL at week 48 weeks of treatment by the IIT-exposed snapshot FDA algorithm;
|
48 weeks
|
Percentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality
Time Frame: From baseline to week 48
|
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline.
The most severe graded abnormality from all tests was counted for each participant.
|
From baseline to week 48
|
Percentage of Participants Experiencing Treatment-Emergent Adverse Events
Time Frame: From baseline to week 48
|
Adverse events (AEs) occurring during treatment and for 30 days following the last dose of study drug were summarized across the participant population.
A participant was counted once if they had a qualifying event.
|
From baseline to week 48
|
Adherence using ACTG form
Time Frame: From baseline to week 48
|
ACTG self report adherence form will be used for baseline and follow up visits
|
From baseline to week 48
|
Adherence using analogue visual scale
Time Frame: From week 4 to week 48
|
Analogue visual scale (0-10) will be used at each follow up visit
|
From week 4 to week 48
|
Adherence by pill count
Time Frame: From week 4 to week 48
|
Pill count of dispensed drugs
|
From week 4 to week 48
|
Quality of life by QoL Socre and Well being index
Time Frame: From baseline to week 48
|
Changes in the scores of quality of life, will be done through Well-being Index questionnaire, this instrument will be administered to patients at baseline, week 4, 24 and week 48 .
|
From baseline to week 48
|
Patient´s satisfaction with this regimen
Time Frame: From baseline to week 48
|
Changes in the scores of social support,will be done through Duke UNC questionnaire, this instrument will be administered to patients at baseline, week 4, 24 and week 48 .
|
From baseline to week 48
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Omar Sued, MD, PhMD, Fundación Huésped
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- HIV Integrase Inhibitors
- Integrase Inhibitors
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- Dolutegravir
Other Study ID Numbers
- FH-17
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on ARV treatment
-
French National Agency for Research on AIDS and...CompletedHIV Infections | AIDSCameroon
-
Centre for Health Systems Research & Development...World Bank; Bank-Netherlands Partnership Programme (BNPP)UnknownHIV Infections | HIV/AIDS | Food InsecuritySouth Africa
-
ANRS, Emerging Infectious DiseasesUniversity of KwaZulu; Africa Centre For Health and Population StudiesCompletedHIV InfectionSouth Africa
-
PfizerArvinas Estrogen Receptor, Inc.Completed
-
PfizerArvinas Estrogen Receptor, Inc.Active, not recruiting
-
Arvinas Androgen Receptor, Inc.Active, not recruitingProstate Cancer MetastaticUnited States
-
Arvinas Androgen Receptor, Inc.RecruitingProstate Cancer MetastaticUnited States
-
PfizerArvinas Estrogen Receptor, Inc.Active, not recruiting
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency Virus I
-
Arvinas Androgen Receptor, Inc.Active, not recruitingProstate Cancer MetastaticCanada, United States, France, United Kingdom